{"name":"Adiso Therapeutics","slug":"adiso-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BT051 200 mg","genericName":"BT051 200 mg","slug":"bt051-200-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BT051 200 mg","genericName":"BT051 200 mg","slug":"bt051-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNUWxocS1uZjlveVdGRU85S0lMMDZ1cXZqNHVnNzRUdFZUVGFVWGVmNWtZTElMRTEwb1dlZ2FIT0tvRjlZMUJoTjgwSEtWX0l2aFdGRTgzUFROT3ZsajZEQ0RxSkQ3eDFtZWs3N3JoLWJpTURadkhLSkVYY09Kai02VXBvTUdJS2cyRkRmMlp4S0NVMXA5LVVLcm9Nc1I2R1RBTE5zUTBvckd0QWFYQWxjNFRVVlVIX0ZvSWRrWlhPTmtWT3NZR3hwejRIRDJZUlZxZ05pd0hFbEZndjBuYXllNE5yQThyckQ0dW91aEMyeEhpOWlBTEhKSQ?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNThzU1RrU09sakFCdlJaOXVVZnZhcjg2OXpIajhaMEk4N25DaF95YXo0Tk9ZakdYRl92bnBLcXZmdkZJaG1YZzVCSFVmSFRmdHpybHhTMEdVQTJQZFNDb1dXYzExZw?oc=5","date":"2025-10-30","type":"pipeline","source":"MedPage Today","summary":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC - MedPage Today","headline":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxPTzcyNm1tRExpN2lEcXlKVmpOeWJHYzhFV1hqaUVsZWNma25HY1d2SkZXalBQNG92ZnlnS1RScElDRFR5VzhxRTg4TXJSLUFxaV9uZkV2VWplbjRoeVMyb2haN0hWU2pDblIxdDRERzFFVjBEbGFINlgyNEZXMHhsMkVlRk03OVRXbTlUb3F1VGo2RVoteVhNS1lYVFBwRHJvWGJaR05kMjJVaWlzQ1VGTk5XcmJldk9HX0RUWkpmV1ZaRTFtWl9XTllXVE1URjJtcjhnWlBGM19KeUNoZm1uRXZRTWhqT3MtQ3MwYllhOGY5QzNsME5MdWtYVFNwSDR2VkNKQVVzalFjVHl0Zkd4TDhPaXRSVHZEVkVlR3p4emQ1WTVqSEZrWjBGR0NYaGJaSmJ2M2xUM0pQUQ?oc=5","date":"2025-03-06","type":"trial","source":"prnewswire.com","summary":"Adiso Therapeutics Announces Data Publication of Two Phase 1 Studies of First-in-Class Neutrophil Modulator ADS051 in the American Journal of Gastroenterology - prnewswire.com","headline":"Adiso Therapeutics Announces Data Publication of Two Phase 1 Studies of First-in-Class Neutrophil Modulator ADS051 in th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQMjBZX0pWcTJKMmVkSWpNWi1pT0FxNFV1NjUybnRYOF9tQVp3UFhlbXphM0J4bDBwbHdDUm1wZXlOTU00T0o3eW95SXdKek00VzhMWWtNN1lmNC0yUGNCMUhPRXNNcmpHRFJIMnJtMFhoVnJNTGg5RzUwQlBmQTlGMzliZ1lPeG0zbkExdlg3bkg1YUJzRFlNY2ltYW5nNnlUNzdxaEg0aTMtOXA3SG93N0FuUnFUWGRBRnBaOXdmekNia3QwVk1lbXVLNElXUXV3aWZKWU5ZaENpWUctZEpwS1ZkSjd2VkdlSEItMGZJaWkzSkFLcFo1TldrRWxUZUw3MFRhOGhvbWIwbV8xLXI1SWFxOHJQdzJCV0wzaTFOdk0?oc=5","date":"2023-10-22","type":"trial","source":"prnewswire.com","summary":"Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis - prnewswire.com","headline":"Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPTk5BQzRONVVmN01BMU52TEZ6UG91T2JBd1BxRVVvdW5iRVhrYXI0empGZFRpdUt6TWxWVWx4UDRNaUhpd1pnU3Qxc1JIVzVpaThrcm0zSkpJZzY0ZURFNnN1c01ubTFnemlQMklkZU5MNkoxdlRQaER2YnB2VjRSb3JYVWZpc01lTmthZlByMlBlVTBEblhpUkh6YTVTNW5RZFpqWk9NVWpBQy1LTGpfTmpDNTdqb0djSmpXNWVOMm1RSUh1VGpocVBOdDJrLTdGX0dUaExR?oc=5","date":"2023-10-16","type":"pipeline","source":"Healio","summary":"‘It is very clear’: Blocking TL1A an important factor in treatment of ulcerative colitis - Healio","headline":"‘It is very clear’: Blocking TL1A an important factor in treatment of ulcerative colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQSmltVVJjdm1YdG44c3QtTFVQbjRBNUhsMzJCTDBZa1AzaXFQOHRUMHVFUVhzY2wxR2xBZzFyeWUwelFyN01LRldwUXcta2huX29jNnlXcUxuaU5kMmwyeE5Fd3I0c1loTWlYMi10M1lyM3ZxR2ZGTl9CQnJjSnJUc21ENGpUSWRUc25QME1Tc2FrbGQxMy1Mb1dJQWM2aXVzel9NWng5VUs?oc=5","date":"2023-02-09","type":"pipeline","source":"citybiz","summary":"Adiso Therapeutics Appoints Srikar Guntaka, M.D., as Medical Director - citybiz","headline":"Adiso Therapeutics Appoints Srikar Guntaka, M.D., as Medical Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOVlRVdjBzN20zdmpIZllFdkVUYzR6ZGVtblgwX3NfUms3ZzhiQmVIS1BoUW9tVUJpbml6bDFpX1lnSlh5WEZKVWVvOU81Zjg1UzZrTnVJSkcwZjdtdDk4V2VoYmozeEVMVGc5NXM0LXhPaUNCNmc4elpXLXBwa2JQaDU1cUptRnZESkE2Qk1aeGY3SnJGRGttUXBGLWFWQ0tPYWx6NDlRejBISW5sSDI1djRlY2RGSGtZVUVHZl9POFNPQnI0Vk9IX1lmTFhEeDZRVm8yaUQyWGRsN1BpNEwyUmZHQQ?oc=5","date":"2022-10-06","type":"pipeline","source":"prnewswire.com","summary":"Adiso Therapeutics Provides Development Update Reflecting Strong Progress Across Its Pipeline - prnewswire.com","headline":"Adiso Therapeutics Provides Development Update Reflecting Strong Progress Across Its Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNY3MxS1BjMXVHTzRhVmhVVEZPMElweXlQWHNJcHFfMnVxSk5Gd2pTUWJ5bjhkNHFxdlQzRTlfUXVMbEIwVDBhRlBIbUNtZG5ERjdubGpPUnVnXzh5NGtMUWJ5OU02R0g1SF8wR21NdnFCZ1JjZ0xtVk56WFRIQlJIYWEtNllvOXJCeHFKZGZMQ1FzRFhGX3R2Nw?oc=5","date":"2022-03-11","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Janssen's US oncology lead jumps to Teon as CEO - Fierce Biotech","headline":"Chutes & Ladders—Janssen's US oncology lead jumps to Teon as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNdWpMdjE0MlR5akVvN3lPMy10RGNQTzQyYWVWREU1dEh0MDE4QWdoT3A5LXg1ZGhNcUtTMzI3bmh4MVFLNHFVX2xtb1JOeUgwc0JyWWRxVVJEOUZWU3R3Z19ublBlaFB2TmFPZ1lxeG05ams0ZFpuQl9HT3lMRE0tLXh3WURfT25CVHhUUXpHSzYxU3FsT0FMYzNfUnN6UWdMcC1kaHVBRm1DNTBIaE9GY1JFb3lZSnd2dDk1ZWcyQzZvWHNaSXBoYWhXdjF6d04xVmxXclVveXlOc3h0RW1XeG1DQUFBOUM2Ulo5SWR3?oc=5","date":"2022-03-10","type":"pipeline","source":"prnewswire.com","summary":"Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases - prnewswire.com","headline":"Morningside Ventures Launches Adiso Therapeutics to Advance Novel Therapies for Inflammatory Diseases","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}